Discovery Chemistry, ‡Cardiovascular and Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, Basel CH-4070, Switzerland.
J Med Chem. 2013 Dec 12;56(23):9789-801. doi: 10.1021/jm401528k. Epub 2013 Nov 22.
Starting from the weakly active dual CatS/K inhibitor 5, structure-based design supported by X-ray analysis led to the discovery of the potent and selective (>50,000-fold vs CatK) cyclopentane derivative 22 by exploiting specific ligand-receptor interactions in the S2 pocket of CatS. Changing the central cyclopentane scaffold to the analogous pyrrolidine derivative 57 decreased the enzyme as well as the cell-based activity significantly by 24- and 69-fold, respectively. The most promising scaffold identified was the readily accessible proline derivative (e.g., 79). This compound, with an appealing ligand efficiency (LE) of 0.47, included additional structural modifications binding in the S1 and S3 pockets of CatS, leading to favorable in vitro and in vivo properties. Compound 79 reduced IL-2 production in a transgenic DO10.11 mouse model of antigen presentation in a dose-dependent manner with an ED50 of 5 mg/kg.
从弱活性双 CatS/K 抑制剂 5 出发,基于结构的设计得到了强活性和选择性(对 CatK 的选择性超过 50,000 倍)的环戊烷衍生物 22,这是通过利用 CatS 的 S2 口袋中特定的配体-受体相互作用实现的。将中环戊烷骨架改为类似的吡咯烷衍生物 57,酶活性和细胞活性分别降低了 24 倍和 69 倍。确定的最有前途的支架是易于获得的脯氨酸衍生物(例如 79)。该化合物的配体效率(LE)为 0.47,包含结合在 CatS 的 S1 和 S3 口袋中的额外结构修饰,从而具有有利的体外和体内性质。化合物 79 以剂量依赖的方式降低了抗原呈递的 DO10.11 转基因小鼠模型中的 IL-2 产生,其 ED50 为 5mg/kg。